secwatch.observer — SEC 8-K summary
======================================

Issuer:     Drugs Made In America Acquisition Corp. (DMAA)
CIK:        0002028614
Form:       8-K
Filed at:   2026-07-20T21:00:13+00:00
Accession:  0001213900-26-079678
Event type: m_and_a
Sentiment:  neutral
Materiality: 0.75
Item codes: 1.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

DMAA amends PAGC merger: sponsor forfeits 50% founder shares, rights buyback $0.25-$0.35, potential three-party deal
--------------------------------------------------------------------------------

- Sponsor to forfeit at least 50% of founder shares; remainder subject to earnout at $12.50/$15.00; 430K private placement rights surrendered.
- Company to commence tender offer for rights at $0.25-$0.35 per right, funded from non-trust sources; rights not tendered remain outstanding.
- Merger consideration recalculated based on fully diluted shares outstanding; minimum cash target $30M, floor $15M.
- Parties in negotiations for potential three-party business combination; contingent Amendment No. 4 pre-approved, effective if LOI signed by Sept 30, 2026.
- Related-party protections: independent fairness opinion required; independent directors to make certain determinations.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/2028614/000121390026079678/0001213900-26-079678-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/2028614/000121390026079678/ea0298461-8k425_drugs.htm
  HTML page:      https://secwatch.observer/filing/0001213900-26-079678

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer